RNA extraction and analysis by real-time quantitative reverse-transcription PCR Total RNA was isolated from the brains of FVB, GtQ226
+/+ and GtE226 +/+ mice using TRIZOL (Invitrogen, Carlsbad, CA). To quantify PrP transcripts, cDNA was synthesized using qScript cDNA synthesis (Quantabio, Beverly, MA), and qRT-PCR was performed using PerfeCTa SYBR green superMix (Quantabio, Beverly, MA) on an Applied Biosystems 75000 platform (Foster City, CA). The β-actin gene was amplified for comparison as an internal control. The forward and reverse primer pairs were as follows: cervid PrP genes for GtQ226 +/+ and GtE226 +/+ 5'-AACCAAGTGTACTACAGGCCA-3' and 5'-TCGGTGAAGTTCTCCCCCTTG-3'; FVB Prnp: 5'-AGAGGCCACAGTAGCAGAGA-3' and 5'-TGCTTGATGAAGGCTCCTGG-3'; mouse β-actin gene: 5'-TGTTACCAACTGGGACGACA-3', 5'-CTGGGTCATCTTTTCACGGT-3'. The qRT-PCR data were analyzed as previously described (2) .
Prion transmission studies All animal work was performed in an AAALAC-accredited facility in compliance with the Guide for the Care and Use of Laboratory Animals. All procedures used in this study were performed in compliance with the Colorado State University Institutional Animal Care and Use Committee. CWD prion isolates were derived from the frozen brains of diseased deer and elk. CWD isolates 99W12389, 012-09442, 001-44720, D10, Db99, red deer, 978-24384, 001-39697, 01-0306, and 04-0306, and cervid-adapted RML and cervid-adapted SSBP/1 have been described previously (3) (4) (5) (6) (7) (8) . Cervid and mouse brains were homogenized to 10 % (wt/vol) in sterile PBS lacking Ca 2+ and Mg 2+ ions. Mice were ic challenged as described previously (4, 9, 10) . Briefly, six to eight-week-old mice were anesthetized with isoflurane prior to free-hand inoculations with 30 µl of 1 % CWD brain homogenates in the front parietal cortex. Following inoculation, all mice were assessed twice weekly for the onset of neurological signs based on standard diagnostic criteria for prion disease (11) . All animals were maintained under standard environmental conditions with a 12 h light:12 h dark cycle, and free access to food and water. For ip challenges, mice were inoculated with 100 µl of 1 % CWD brain homogenates using a 26-gauge needle. For po challenges, mice were gavaged with 100 µl of 1 % of brain homogenate with a 20GX 1-1/2 animal feeding needle. Following euthanasia, the brains of a subset of diseased mice were removed and bisected down the midline, one hemisphere being frozen for biochemical analyses, and the other immersion fixed in formalin for neuropathological assessments. The brains of other diseased mice were taken whole and either fixed in formalin, or snap frozen for histoblot analysis.
Analysis of PrP
Sc Western blotting of CNS PrP Sc was performed and analyzed as previously described (10) . Whole spleens were homogenized to 10 % (w/v) in PBS containing protease and phosphatase inhibitors (SIGMA), and protein concentration was determined by bicinchoninic acid (BCA) assay (Pierce). Spleen homogenates were treated with 0.1 -1 mg/ml DNase I (Sigma) and 5 mM MgCl2 for 30 minutes at 37°C with gentle agitation. DNase-treated spleen homogenates (1 mg) were treated with 50 µg/ml PK and 2 % sarcosyl for 1 h at 37°C with gentle agitation. PK digestion was terminated with 2 mM PMSF for 10 min at room temperature. Samples were subjected to ultracentrifugation at 100,000 x g for 1 h at 4°C. Pellets were suspended in 50 µl SDS-PAGE sample loading buffer, denatured at 100°C for 10 min, and subjected to SDS-PAGE and western blotting with chemiluminescent detection. Histoblots were produced and analyzed according to previously described protocols (12) (13) (14) . IHC of PrP Sc in fixed brains was performed as previously described (13, 14) .
Conformational Stability Assay
Brain homogenates containing 5 µg protein were incubated with various concentrations of GdnHCl in 96-well plates for 1 h at room temperature. Samples were adjusted with PBS to 0.4 M GdnHCl and transferred onto nitrocellulose (Whatman GmbH, Dassel, Germany) using a dot blot apparatus. After two PBS washes, the membrane was air-dried for 1 h, then incubated with 5 µg/ml PK in cell lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 % sodium deoxycholate, 0.5 % Igepal CA-630) for 1 h at 37°C. PK was then inactivated with 2 mM PMSF. The membranes were then denatured in 3 M guanidine thiocyanate in Tris-HCl, pH 7.8 for 10 min at room temperature. After four washes with PBS, the membrane was blocked with 5 % nonfat milk in TBST for 1 h and probed with mAb PRC5 (15) (1∶5000) overnight at 4°C, followed by HRP-conjugated goat anti-mouse IgG secondary antibody. The membrane was developed with ECL Plus and scanned with an ImageQuant LAS 4000 (GE Healthcare). The signal was analyzed with ImageQuant TL 7.0 software (GE Healthcare). Time to disease onset (incubation time) is expressed as the mean time, in days, at which inoculated mice first developed ultimately progressive signs of neurological disease. Variance is expressed as ± standard error of the mean (SEM). n/no, number of diseased mice/number of inoculated mice. Mice dying of unrelated intercurrent illnesses were excluded from these calculations. *, transmissions previously reported in (5, 6, 8) .
